You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,539,245

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,539,245

Title:	Combination of immunotherapies with activators of Tie-2
Abstract:	The present invention relates to combination therapies comprising at least one activator of Tie-2 and immunotherapies that target immune checkpoints. Combination therapies of the disclosure can provide therapeutic effects not obtained with singly-administered immunotherapies. Combination therapies can be used to increase the therapeutic efficacy of an immunotherapy, to provide lower dosages of an immunotherapy being administered, to lower a toxicity of an immunotherapy, or to manage a side effect of an immunotherapy.
Inventor(s):	Peters; Kevin (Cincinnati, OH)
Assignee:	AERPIO THERAPEUTICS, INC. (Cincinnati, OH)
Application Number:	14/819,871
Patent Claims:	1. A method of treating cancer, the method comprising administering to a subject in need thereof: a) a therapeutically-effective amount of a Tie-2 activator; and b) a therapeutically-effective amount of a modulator of an immune checkpoint molecule. 2. The method of claim 1, wherein the Tie-2 activator binds a phosphatase. 3. The method of claim 1, wherein the Tie-2 activator inhibits a phosphatase. 4. The method of claim 1, wherein the Tie-2 activator binds HPTP.beta.. 5. The method of claim 1, wherein the Tie-2 activator inhibits HPTP.beta.. 6. The method of claim 1, wherein the Tie-2 activator is: ##STR00022## or a pharmaceutically-acceptable salt thereof. 7. The method of claim 1, wherein the immune checkpoint molecule is LAGS. 8. The method of claim 1, wherein the immune checkpoint molecule is BTLA. 9. The method of claim 1, wherein the immune checkpoint molecule is KIR. 10. The method of claim 1, wherein the immune checkpoint molecule is CTLA4. 11. The method of claim 1, wherein the immune checkpoint molecule is ICOS. 12. The method of claim 1, wherein the immune checkpoint molecule is TIM3. 13. The method of claim 1, wherein the immune checkpoint molecule is A2aR. 14. The method of claim 1, wherein the immune checkpoint molecule is PD-1. 15. The method of claim 1, wherein the modulator of the immune checkpoint molecule is ipilimumab. 16. The method of claim 1, wherein the modulator of the immune checkpoint molecule is nivolumab. 17. The method of claim 1, wherein the modulator of the immune checkpoint molecule is tremelimumab. 18. The method of claim 1, wherein the modulator of the immune checkpoint molecule is A-dmDT390-bisFv(UCHT1). 19. The method of claim 1, wherein the therapeutically-effective amount of the Tie-2 activator is from about 1 mg to about 100 mg. 20. The method of claim 1, wherein the therapeutically-effective amount of the Tie-2 activator is about 15 mg. 21. The method of claim 1, wherein the Tie-2 activator and the modulator of the immune checkpoint molecule are administered in the same unit dosage form. 22. The method of claim 1, wherein the subject is human. 23. A pharmaceutical composition comprising: a) a Tie-2 activator; and b) a modulator of an immune checkpoint molecule, wherein the Tie-2 activator and the modulator of the immune checkpoint molecule are in the same unit dosage form. 24. The pharmaceutical composition of claim 23, wherein the Tie-2 activator binds a phosphatase. 25. The pharmaceutical composition of claim 23, wherein the Tie-2 activator inhibits a phosphatase. 26. The pharmaceutical composition of claim 23, wherein the Tie-2 activator binds HPTP.beta.. 27. The pharmaceutical composition of claim 23, wherein the Tie-2 activator inhibits HPTP.beta.. 28. The pharmaceutical composition of claim 23, wherein the Tie-2 activator is: ##STR00023## or a pharmaceutically-acceptable salt thereof. 29. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is LAG3. 30. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is BTLA. 31. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is KIR. 32. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is CTLA4. 33. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is ICOS. 34. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is TIM3. 35. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is A2aR. 36. The pharmaceutical composition of claim 23, wherein the immune checkpoint molecule is PD-1. 37. The pharmaceutical composition of claim 23, wherein the modulator of the immune checkpoint molecule is ipilimumab. 38. The pharmaceutical composition of claim 23, wherein the modulator of the immune checkpoint molecule is nivolumab. 39. The pharmaceutical composition of claim 23, wherein the modulator of the immune checkpoint molecule is tremelimumab. 40. The pharmaceutical composition of claim 23, wherein the modulator of the immune checkpoint molecule is A-dmDT390-bisFv(UCHT1).

Details for Patent 9,539,245

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011	⤷ Try a Trial	2034-08-07
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014	⤷ Try a Trial	2034-08-07
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017	⤷ Try a Trial	2034-08-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.